$2,41
▼ $-0,12
(-4,74%)
Vol. 1.3M
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$170.3M
ROE
-123,0%
Margine
-156,0%
D/E
16,65
Beta
0,65
52W
$1–$3
Consenso Wall Street
13 analisti · Apr 20261
Acquisto forte
1
Compra
6
Mantieni
3
Vendi
2
Vendita forte
15,4%
Rating Compra
Grafico dei Prezzi
Titoli simili
TARA
Protara Therapeutics Inc
$275.2M
CCCC
C4 Therapeutics Inc
$185.1M
ABEO
Abeona Therapeutics Inc
P/E 3,5
$285.6M
EDIT
Editas Medicine Inc
$200.1M
TLSI
TriSalus Life Sciences Inc
$348.8M
CHRS
Coherus Oncology Inc
P/E 1,1
$171.6M
ALXO
ALX Oncology Holdings Inc
$61.3M
TENX
Tenax Therapeutics Inc
$76.1M
Utili
Tasso di battuta: 100,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,39 | $-0,34 | +$0,05 |
| Set 2025 | $-0,42 | $-0,34 | +$0,08 |
| Giu 2025 | $-0,47 | $-0,30 | +$0,17 |
| Mar 2025 | $-0,49 | $-0,41 | +$0,08 |
Ricavi e utili trimestrali
| Trimestre | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Ricavi | $54.2M | $3.7M | $7.9M | $3.3M | $6.2M |
| Utile netto | -$2.1M | -$40.5M | -$30.5M | -$34.7M | -$37.3M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -112.1% | -112.1% | -112.1% | -112.1% | -123.0% | -123.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -387.7% | -142.1% | -142.1% | -142.1% | -156.0% | -156.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 13.40 | 13.40 | 13.40 | 13.40 | 16.65 | 16.65 |
| Current Ratio | 3.78 | 3.78 | 3.78 | 3.78 | 3.76 | 3.76 |
Rapporti chiave
ROA (TTM)
-27,5%
P/S (TTM)
2,47
P/B
1,5
EPS (TTM)
$-1,07
CF/Share
$-1,58
Crescita ricavi 3A
-21,4%
52W High
$3,40
52W Low
$0,87
$0,87
Intervallo 52 settimane
$3,40
Salute finanziaria
Flusso di cassa libero
-$41.7M
Debito netto
-$29.6M
Liquidità
$65.8M
Debito totale
$36.2M
Aggiornato al Dic 31, 2025
Як ALEC виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ALEC vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
2,5
▼
81%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
1,5
▼
41%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ALEC vs аналоги Biotechnology
ROE
-123,0%
▼
83%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-156,0%
▲
46%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-27,5%
▲
41%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя ALEC vs аналоги Biotechnology
D/E ratio
16,7
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
3,8
▼
15%
sotto
peer
(4,4)
vs Peer
vs Settore
In linea
Beta
0,7
▼
33%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ALEC
ALEC
Mediana peer
Industria
ALEC прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ALEC vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
ROSENTHAL ARNON
Chief Executive Officer · Mar 13
116246 shs
BERKLEY NEIL LINDSAY
Chief Financial Officer · Mar 13
54600 shs
WONG-SARAD GRACE
Officer · Mar 10
1000 shs
WONG-SARAD GRACE
Officer · Mar 03
3367 shs
BERKLEY NEIL LINDSAY
Chief Financial Officer · Mar 02
29649 shs
WONG-SARAD GRACE
Officer · Mar 02
8071 shs
ROSENTHAL ARNON
Chief Executive Officer · Mar 02
81864 shs
WONG-SARAD GRACE
Officer · Feb 26
4079 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 28,53%TCG Crossover Management, L…
9,06%
$20.0M
Blackrock Inc.
6,48%
$14.3M
Vanguard Group Inc
6,26%
$13.8M
Foresite Capital Management…
3,52%
$7.8M
Merck & Co., Inc.
3,21%
$7.1M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora